Mr. Steinberg stated, “Pacira remains one of the rare ‘hyper growth’ stories in life sciences — with stellar execution leading to Exparel annualizing at $180M (just 1.6 percent share) after nine quarters.”
Pacira Pharmaceuticals’ shares closed yesterday at $101.85.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
